Mycophenolate Mofetil (CellCept)
Prodrug ester of mycophenolic acid (MPA), a selective reversible inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH) that depletes guanosine nucleotides preferentially in lymphocytes. First-line for solid-organ transplant maintenance immunosuppression (typically with tacrolimus + steroid taper) and for lupus nephritis, AIHA, myasthenia gravis, and other autoimmune conditions. Typical adult dose 500-1500 mg PO BID (2-3 g/day transplant). MMF is rapidly hydrolyzed to MPA (F~94%); MPA t1/2 ~18h with enterohepatic recirculation producing a secondary peak. GI toxicity (diarrhea, nausea) and myelosuppression are leading AEs; teratogenic, strict pregnancy prevention required (REMS).
Projected serum levels — 1k mg, twice daily
Maintenance schedule: 1k mg twice daily (oral).
Loading schedule: 1.4k mg on day 1, then 1k mg twice daily — reaching therapeutic levels sooner.
Modeled steady state after ~1 days: peak ≈ 190 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 1k mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Immunosuppressant
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 18 h
- Common dose
- 1k mg
- Suggested maximum
- 3k mg/day
- Reference dose range
- 500–3k mg (single dose)
- Suggested cadence
- twice daily
- Validated against
- 1k mg oral — Cmax 24.5 mg/L at 1 h
Documented interactions
-
danger
Levothyroxine (Synthroid) + Mycophenolate Mofetil (CellCept)
Mycophenolate Mofetil (CellCept) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…
-
danger
Tacrolimus (Prograf) + Mycophenolate Mofetil (CellCept)
Mycophenolate Mofetil (CellCept) may displace Tacrolimus (Prograf) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…
-
danger
Warfarin (Coumadin) + Mycophenolate Mofetil (CellCept)
Mycophenolate Mofetil (CellCept) may displace Warfarin (Coumadin) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free…
-
warning
Apigenin + Mycophenolate Mofetil (CellCept)
Mycophenolate Mofetil (CellCept) may displace Apigenin from plasma protein binding sites, transiently raising free drug concentration.
-
warning
Aripiprazole (Abilify) + Mycophenolate Mofetil (CellCept)
Mycophenolate Mofetil (CellCept) may displace Aripiprazole (Abilify) from plasma protein binding sites, transiently raising free drug concentration.
-
warning
Armour Thyroid (Desiccated Thyroid Extract) + Mycophenolate Mofetil (CellCept)
Mycophenolate Mofetil (CellCept) may displace Armour Thyroid (Desiccated Thyroid Extract) from plasma protein binding sites, transiently raising free drug concentration.
Serum checks 143 modeled interaction pairings for mycophenolate mofetil (cellcept) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Clinical pharmacokinetics of mycophenolate mofetil
Foundational PK review: MMF rapidly hydrolyzed to MPA (F~94%), MPA t1/2 ~18h, enterohepatic recirculation produces secondary peak, glucuronide metabolism dominates elimination.
-
Therapeutic drug monitoring of mycophenolate mofetil in transplantation
Consensus TDM guidance: MPA AUC 30-60 mg.h/L target in renal transplant, C0 trough targets, and PK variability justifying dose individualization.
2 published studies referenced in the app, each with a plain-language summary.